Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05837845 · ClinicalTrials.gov registry record · Phase 2
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
A Phase 2 study of PTSD, sponsored by Patricia Suppes.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05837845: Recruiting Phase 2 study of PTSD, sponsored by Patricia Suppes.
NCT05837845 is a Phase 2 study of PTSD that is actively recruiting participants, run by Patricia Suppes. The registered enrollment target is 30 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05837845, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by Patricia Suppes.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.
Primary Outcome
The Primary Outcome measure will be the change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score from Baseline to 4 months post-baseline assessed by a blinded study staff rater. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Processing Therapy
- DRUG MDMA
- BEHAVIORAL MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Study Locations (1)
California
- VA Palo Alto Health Care System / Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT05837845 shows while recruiting
NCT05837845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Processing Therapy is the first listed.
NCT05837845 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05837845 about?
NCT05837845 is a clinical study titled "MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder". In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stres...
What is the current status of trial NCT05837845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-10. Estimated completion is 2027-12.
What conditions does trial NCT05837845 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT05837845?
The interventions under investigation include: Cognitive Processing Therapy (BEHAVIORAL), MDMA (DRUG), MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05837845?
This trial is sponsored by Patricia Suppes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05837845 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05837845's enrollment target sits among peer trials
30 122nd of 154 higher than 25 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
-
Intranasal Insulin for Posttraumatic Stress Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI